Two COVID-19 vaccines developed in Seattle got the nod from regulatory agencies outside the U.S. this week. A University of Washington shot is ready for rollout in South Korea, and a shot linked to HDT Bio won emergency use approval in India. The UW shot is the first approved medicine based on computational protein design, “To me that is a watershed moment,” UW researcher Neil King told GeekWire earlier this month.
Read on for more life sciences news this week in the Pacific Northwest.
Clinical trials and studies:
- Fred Hutch researcher Jesse Bloom and his colleagues published a study outlining key teps in the evolution of Omicron and other COVID-19 variants.
- South San Francisco and Vancouver, B.C.-based ESSA Pharma’s experimental therapy for prostate cancer showed “initial anti-tumor activity” in an early-stage study.
- Seattle-area medical device company LumiThera reported data on its trial treating age-related macular degeneration with a type of light therapy.
- Black women were more likely than white women to experience delays in obtaining a breast biopsy than white women, according to a UW-led study. The findings suggest that systemic racism may be a factor.
Approvals and deals:
- Bristol Myers Squibb’s CAR T cell cancer therapy Breyanzi, manufactured in the Seattle area, was approved to treat patients at an earlier stage of disease.
- Arzeda, a Seattle company that designs proteins for industrial use, announced a collaboration with global materials science company W. L. Gore & Associates.
- Vancouver B.C.-based Poda, which developed nicotine-delivery devices, completed a $100.5 million sale to Altria Group.
In case you missed it:
- Affini-T Therapeutics announced a partnership with gene editing company Metagenomi. Affini-T, which has operations in Seattle, will apply Metagenomi’s tech to its T cell receptor therapies directed against cancer-causing genes.
- Healthcare innovation collaborative Matter launched an incubation program with Amazon Web Services to prepare startups from Europe, Africa and the Middle East to understand and enter the U.S. healthcare market.